• Acino in Latin America
    • Company Profile
    • Our Culture
    • Our Management
    • Our History
  • Services
    • We Partner
    • We Market
  • Products
  • We Care
  • Media
  • Careers
  • Contact Us
Portuguese (Brazil)Spanish
  • Acino in Latin America
    • Company Profile
    • Our Culture
    • Our Management
    • Our History
  • Services
    • We Partner
    • We Market
  • Products
  • We Care
  • Media
  • Careers
  • Contact Us

We use cookies to create statistics that help us to improve the quality of our website and your user experience. By clicking on “Accept All”, you consent to the processing of data by Acino and the transfer of data to third parties. You can also tailor your consent for specific data processing purposes. Once you have made your choice, click on “Confirm”. Find detailed information and modify your preferences at any time in our Privacy Notice.

Necessary Cookies Always Active

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics Cookies

We would like to set Google Analytics cookies to help us analyse the traffic on our website.

02.12.2024

Leadership Announcements and New Arcera Structure

Arcera aims to become a global life sciences company, with the purpose of enabling longer and healthier lives while driving...

01.10.2024

Acino Publishes Second Annual Sustainability Report

Report underscores Acino’s continued commitment to Environmental, Social, and Governance goals, including a firm commitment to reaching full carbon neutrality...

29.09.2024

Acino Recognizes World Heart Day 2024

Acino reaffirms its commitment to advancing cardiovascular health in emerging markets and beyond.

24.07.2024

Acino signs an exclusive agreement with LG Chem for Novel Treatments for Type 2 Diabetes and Osteoarthritis in Latin America

Acino will market, commercialize, and distribute Hyruan One® in Brazil, and Zemiglo® and Zemimet® SR (Zemiduo® SR in Mexico) in...

26.06.2024

Your partner for innovative medicines in emerging markets

We have expanded our portfolio with several novel products, marking a significant step forward in our effort to help more...

07.05.2024

Acino signs an exclusive license agreement with Supernus in Latin America

Acino will collaborate with Supernus to develop and commercialize products for the treatment of diseases of the central nervous system...

02.04.2024

Acino announces new regional leadership and hub to deliver on expanded presence and capabilities in Latin America following M8 acquisition

Joel Barlan has been appointed as Head of the LATAM region. Mexico City will now serve as a regional hub...

20.03.2024

Acino signs an exclusive license agreement with SERB Pharmaceuticals in Latin America

We are collaborating to bring an important orphan drug for cancer patients to Latin America.

04.12.2023

Acino Completes Acquisition of M8 Pharmaceuticals Significantly Expanding Presence and Capabilities in Latin America

Acino will enhance its presence in Latin America and strengthen its business through new partnerships, innovative and proven portfolio and...

Contact UsReport an Adverse Event
Acino - Part of Arcera
  • Acino in Latin America
  • Company Profile
  • Our Culture
  • Our Management
  • Our History
  • Services
  • We Partner
  • We Market
  • Products
  • We Care

  • Privacy
  • Terms of Use
  • Social Media Community Guidelines
Back to top

© 2026 Acino Latinoamericana S.A.

This site is intended for audiences in Latin America and provides general information about our products to a wide range of consumers. Some content may not be available or applicable in your country. Please note that we are not responsible for your access to such content. For country-specific information, we recommend consulting your local regulatory authorities. For medical advice, always seek guidance from a qualified healthcare professional.